论文部分内容阅读
目的:分析大面积脑梗塞应用血塞通联合依达拉奉治疗的临床价值。方法:随机抽取2009年~2012年在我院进行治疗的大面积脑梗塞患者60例的临床资料进行回顾性分析,根据治疗方法的不同将其分为对照组和观察组两组,对照组30例患者进行常规依达拉奉治疗,观察组30例患者在常规治疗的基础上应用血塞通治疗,比较两组患者的临床效果。结果:治疗后,观察组患者的有效率为93.3%,对照组患者的有效率为66.7%,两组患者的有效率比较差异有统计学意义(P<0.05)。结论:大面积脑梗塞患者应用血塞通联合依达拉奉治疗能够取得良好的临床效果,且不良反应发生少,可以在临床上广泛推广。
Objective: To analyze the clinical value of Xuesaitong combined with edaravone in treating large area cerebral infarction. Methods: The clinical data of 60 patients with massive cerebral infarction who were treated in our hospital from 2009 to 2012 were randomly selected. The clinical data of 60 patients were divided into control group and observation group according to the different treatment methods. The control group 30 The patients were treated with conventional edaravone. 30 patients in the observation group were treated with Xuesaitong on the basis of routine treatment, and the clinical effects of the two groups were compared. Results: After treatment, the effective rate of the observation group was 93.3%, while that of the control group was 66.7%. There was significant difference between the two groups in the effective rate (P <0.05). Conclusion: The application of Xuesaitong combined with edaravone in patients with large area cerebral infarction can achieve good clinical results, and fewer adverse reactions, which can be widely popularized in clinic.